The Role of Biomarkers, Metabolomics, and COVID-19 in Venous Thromboembolism—A Review of Literature

In recent years, the field of venous thromboembolism has undergone numerous innovations, starting from the recent discoveries on the role of biomarkers, passing through the role of metabolomics in expanding our knowledge on pathogenic mechanisms, which have opened up new therapeutic targets. A variety of studies have contributed to characterizing the metabolic phenotype that occurs in venous thromboembolism, identifying numerous pathways that are altered in this setting. Among these pathways are the metabolism of carnitine, tryptophan, purine, and fatty acids. Furthermore, new evidence has emerged with the recent COVID-19 pandemic. Hypercoagulability phenomena induced by this viral infection appear to be related to altered von Willebrand factor activity, alteration of the renin–angiotensin–aldosterone system, and dysregulation of both innate and adaptive immunity. This is the first literature review that brings together the most recent evidence regarding biomarkers, metabolomics, and COVID-19 in the field of venous thromboembolism, while also mentioning current therapeutic protocols.

[1]  P. Lutsey,et al.  Epidemiology and prevention of venous thromboembolism , 2022, Nature Reviews Cardiology.

[2]  Zhengye Liu,et al.  Serum Albumin and Circulating Metabolites and Risk of Venous Thromboembolism: A Two-Sample Mendelian Randomization Study , 2021, Frontiers in Nutrition.

[3]  S. Stevens,et al.  Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. , 2021, Chest.

[4]  Beata Franczyk,et al.  Metabolomic Profile in Venous Thromboembolism (VTE) , 2021, Metabolites.

[5]  A. Davies,et al.  Metabolic Profiling Reveals Changes in Serum Predictive of Venous Ulcer Healing , 2021, Annals of surgery.

[6]  S. Spinler,et al.  COVID-19 and thrombosis: From bench to bedside , 2020, Trends in Cardiovascular Medicine.

[7]  D. Trégouët,et al.  Plasma Biomarkers and Identification of Resilient Metabolic Disruptions in Patients With Venous Thromboembolism Using a Metabolic Systems Approach , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Aepfelbacher,et al.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[9]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[10]  Xiaosheng Wang,et al.  Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues , 2020, Infectious Diseases of Poverty.

[11]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[12]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[13]  J. Coons,et al.  Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism , 2020, Pharmacotherapy.

[14]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[15]  Mostafa E. Belghasem,et al.  Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis. , 2019, Blood.

[16]  A. Davies,et al.  Metabolic Phenotyping in Venous Disease: The Need for Standardization. , 2019, Journal of proteome research.

[17]  P. Faries,et al.  Virchow's triad in "silent" deep vein thrombosis. , 2019, Journal of vascular surgery. Venous and lymphatic disorders.

[18]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) , 2019, European Respiratory Journal.

[19]  M. Prins,et al.  Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis , 2019, BMJ.

[20]  T. Hirai,et al.  Higher lactate and purine metabolite levels in erythrocyte-rich fresh venous thrombus: Potential markers for early deep vein thrombosis. , 2019, Thrombosis research.

[21]  A. Davies,et al.  Metabolomics as a tool to improve decision making for the vascular surgeon - wishful thinking or a dream come true? , 2019, Vascular pharmacology.

[22]  Paolo Prandoni,et al.  Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. , 2018, European heart journal.

[23]  P. Kraft,et al.  Metabolites Associated With the Risk of Incident Venous Thromboembolism: A Metabolomic Analysis , 2018, Journal of the American Heart Association.

[24]  M. Fischbach,et al.  Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential , 2018, Circulation research.

[25]  Mohamed H. Shahin,et al.  Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism. , 2018, Thrombosis research.

[26]  A. Davies,et al.  Deep Vein Thrombosis Exhibits Characteristic Serum and Vein Wall Metabolic Phenotypes in the Inferior Vena Cava Ligation Mouse Model. , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[27]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[28]  F. Rosendaal,et al.  Lipid levels and risk of venous thrombosis: results from the MEGA-study , 2017, European Journal of Epidemiology.

[29]  E. Antman,et al.  Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial , 2016, Journal of the American Heart Association.

[30]  P. Simioni,et al.  New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[31]  G. Raskob,et al.  Global Burden of Thrombosis: Epidemiologic Aspects. , 2016, Circulation research.

[32]  T. Wakefield,et al.  1D-¹H-nuclear magnetic resonance metabolomics reveals age-related changes in metabolites associated with experimental venous thrombosis. , 2016, Journal of vascular surgery. Venous and lymphatic disorders.

[33]  S. Hazen,et al.  Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk , 2016, Cell.

[34]  M. Weatherall,et al.  Venous thromboembolism risk associated with protracted work- and computer-related seated immobility: A case-control study , 2016, JRSM open.

[35]  C. Zielinski,et al.  Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. , 2016, The oncologist.

[36]  X. Ming,et al.  A tryptophan derivative TD-26 attenuates thrombus formation by inhibiting both PI3K/Akt signaling and binding of fibrinogen to integrin αIIbβ3. , 2015, Biochemical and biophysical research communications.

[37]  José A Fernández,et al.  Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. , 2015, Blood.

[38]  Xiaobing Fu,et al.  Impaired wound healing results from the dysfunction of the Akt/mTOR pathway in diabetic rats. , 2015, Journal of dermatological science.

[39]  F. Rey,et al.  Intestinal Microbiota Composition Modulates Choline Bioavailability from Diet and Accumulation of the Proatherogenic Metabolite Trimethylamine-N-Oxide , 2015, mBio.

[40]  Murali Krishna Gurram,et al.  Effectiveness of D-Dimer as a Screening Test for Venous Thromboembolism: An Update , 2014, North American journal of medical sciences.

[41]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[42]  V. Fuster,et al.  Metabolomics reveals metabolite changes in acute pulmonary embolism. , 2014, Journal of proteome research.

[43]  P. Kamphuisen,et al.  Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism. , 2013, American journal of respiratory and critical care medicine.

[44]  K. Guire,et al.  Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis. , 2013, Journal of vascular surgery. Venous and lymphatic disorders.

[45]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[46]  M. Hori,et al.  Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[47]  Wei Liu,et al.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC , 2012, Proceedings of the National Academy of Sciences.

[48]  P. Ray,et al.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.

[49]  T. Baglin.  Inherited and Acquired Risk Factors for Venous Thromboembolism , 2012, Seminars in Respiratory and Critical Care Medicine.

[50]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[51]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[52]  Y. Merhi,et al.  P-selectin ligation induces platelet activation and enhances microaggregate and thrombus formation. , 2011, Thrombosis research.

[53]  P. Simioni,et al.  Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. , 2011, Thrombosis research.

[54]  B. Dezső,et al.  Lack of P-selectin glycoprotein ligand-1 protects mice from thrombosis after collagen/epinephrine challenge. , 2011, Thrombosis research.

[55]  C. Kluft,et al.  A thrombin generation assay may reduce the need for compression ultrasonography for the exclusion of deep venous thrombosis in the elderly , 2011, Scandinavian journal of clinical and laboratory investigation.

[56]  M. Prins,et al.  Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. , 2010, European journal of internal medicine.

[57]  B. Nordestgaard,et al.  C-Reactive Protein and Risk of Venous Thromboembolism in the General Population , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[58]  T. Morgenthaler,et al.  Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. , 2010, Chest.

[59]  N. Key,et al.  Membrane microparticles in VTE and cancer. , 2010, Thrombosis research.

[60]  T. Ortel,et al.  Venous thromboembolism: a public health concern. , 2010, American journal of preventive medicine.

[61]  T. van der Poll,et al.  Inflammation and coagulation , 2010, Critical care medicine.

[62]  A. Folsom,et al.  C-reactive protein and venous thromboembolism , 2009, Thrombosis and Haemostasis.

[63]  J. Gore,et al.  Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study , 2009, Journal of Thrombosis and Thrombolysis.

[64]  S. Eichinger,et al.  Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. , 2008, Clinical chemistry.

[65]  J. Douketis,et al.  Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism , 2008, Annals of Internal Medicine.

[66]  M. Makris,et al.  Thrombin generation testing in routine clinical practice: are we there yet? , 2008, British journal of haematology.

[67]  P. Moerloose,et al.  D‐Dimer for venous thromboembolism diagnosis: 20 years later , 2008, Journal of thrombosis and haemostasis : JTH.

[68]  L. Almasy,et al.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. , 2007, Blood.

[69]  H R Büller,et al.  Diagnostic accuracy of D‐dimer test for exclusion of venous thromboembolism: a systematic review , 2007, Journal of thrombosis and haemostasis : JTH.

[70]  Frits R Rosendaal,et al.  Inflammatory Cytokines as Risk Factors for a First Venous Thrombosis: A Prospective Population-Based Study , 2006, PLoS medicine.

[71]  A. Kaider,et al.  Interleukin-6 and interleukin-6 promoter polymorphism (−174) G>C in patients with spontaneous venous thromboembolism , 2006, Thrombosis and Haemostasis.

[72]  K. Mann,et al.  Thrombin generation profiles in deep venous thrombosis , 2005, Journal of thrombosis and haemostasis : JTH.

[73]  L. Horstman,et al.  Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. , 2005, Journal of the American College of Cardiology.

[74]  É. Hajduch,et al.  Ceramide down‐regulates System A amino acid transport and protein synthesis in rat skeletal muscle cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  A. Schmaier,et al.  D-dimer, P-selectin, and microparticles: Novel markers to predict deep venous thrombosis , 2004, Thrombosis and Haemostasis.

[76]  B. Furie,et al.  Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. , 2004, Trends in molecular medicine.

[77]  A. Hafezi-Moghadam,et al.  Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A , 2003, Nature Medicine.

[78]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[79]  K. Ley.  The role of selectins in inflammation and disease. , 2003, Trends in molecular medicine.

[80]  P. Romano,et al.  Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.

[81]  R P McEver,et al.  Adhesive Interactions of Leukocytes, Platelets, and the Vessel Wall during Hemostasis and Inflammation , 2001, Thrombosis and Haemostasis.

[82]  S. Summers,et al.  Ceramide dissociates 3'-phosphoinositide production from pleckstrin homology domain translocation. , 2001, The Biochemical journal.

[83]  L. Greenfield,et al.  IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. , 1998, Journal of immunology.

[84]  M. Mitchell,et al.  Urinary, plasma, and erythrocyte carnitine concentrations during transition to a lactoovovegetarian diet with vitamin B-6 depletion and repletion in young adult women. , 1998, The American journal of clinical nutrition.

[85]  L. Osnes,et al.  Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. , 1996, Cytokine.

[86]  C. Benjamin,et al.  Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets , 1992, Nature.

[87]  R. Cummings,et al.  Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells , 1992, The Journal of cell biology.

[88]  Rodger P. McEver,et al.  Rapid neutrophil adhesion to activated endothelium mediated by GMP-140 , 1990, Nature.

[89]  J. Westwick,et al.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. , 1982, British medical journal.

[90]  E. J. Pulaski,et al.  The Treatment of Venous Thrombosis With Heparin*† , 1953, Angiology.

[91]  M. Debakey,et al.  THERAPY OF PHLEBOTHROMBOSIS AND THROMBOPHLEBITIS , 1940 .

[92]  Cui Hao,et al.  Low molecular weight heparins and their clinical applications. , 2019, Progress in molecular biology and translational science.

[93]  K. Kalantar-Zadeh,et al.  Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[94]  S. Kahn.  The post-thrombotic syndrome. , 2016, Hematology. American Society of Hematology. Education Program.

[95]  D. Xavier,et al.  Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. , 2015, American heart journal.

[96]  Gordon H. Guyatt,et al.  Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 2011 .

[97]  S. Summers,et al.  Ceramides in insulin resistance and lipotoxicity. , 2006, Progress in lipid research.

[98]  B. Cosmi,et al.  Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped , 2002, Thrombosis and Haemostasis.

[99]  J. Badimón,et al.  Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. , 2000, Blood.